Drugmaker Pfizer (PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are expecting earnings per share to come in at $0.63 on revenue of $16.51 billion. This compares to last year’s figures of $1.06 and $17.7 billion, respectively. Interestingly, Pfizer has a solid track record when it comes to beating earnings, as it has done so in 15 of its last 16 quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nevertheless, investors will be keeping an eye on the company’s late-stage pipeline progress. This includes Elrexfio for multiple myeloma and Sigvotatug Vedotin for non-small cell lung cancer, both of which could significantly boost long-term revenue if successful. Investors may also look for updates on Pfizer’s vaccine programs for C. difficile and Lyme disease, which are in Phase III testing.
Moreover, investors will likely be seeking more clarity regarding Pfizer’s new legal battle with Novo Nordisk (NVO) over the acquisition of Metsera (MTSR). Indeed, Novo Nordisk swooped in with a higher bid, which led Pfizer to sue both companies. However, the most important factor will be how Trump’s policies impact the firm’s American operations, since the U.S. makes up the majority of sales, as shown below.
What Do Options Traders Anticipate?
Using TipRanks’ Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. Indeed, the at-the-money straddle suggests that options traders expect a 4.7% price move in either direction. This estimate is derived from the $24.5 strike price, with call options priced at $0.56 and put options at $0.60.
Is PFE Stock a Buy?
Turning to Wall Street, analysts have a Hold consensus rating on Pfizer stock based on four Buys, 12 Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average Pfizer price target of $28.60 per share implies 15.7% upside potential. At the same time, TipRanks’ AI analyst has an Outperform rating and a $28 price target.
